George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Share News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.00
Bid: 61.00
Ask: 65.00
Change: 0.00 (0.00%)
Spread: 4.00 (6.557%)
Open: 63.00
High: 63.00
Low: 63.00
Prev. Close: 63.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens

Thu, 28th Sep 2023 14:24

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Dar Global PLC - luxury international real estate developer - In the six months that ended June 30, pretax profit multiplies to GBP20.8 million from GBP3.7 million a year earlier. Revenue also multiplies to GBP108.4 million from GBP27.5 million. Chief Executive Officer Ziad El Chaar says: "2023 has been a milestone year for the company with our successful listing on the London Stock Exchange in February representing a significant step forward in supporting our ambitious growth trajectory. The second half has started strongly and we are well positioned to weather some of the challenges facing the sector through the strength of our balance sheet, building partnerships with other global luxury brands and further expanding our pipeline of opportunities."

----------

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - In the six months that ended June 30, pretax loss widens to GBP4.3 million from GBP1.1 million. Posts no revenue, unchanged, while administrative expenses widen to GBP3.9 million from GBP1.1 million. Chief Executive Officer Vladislav Sandler says: "While the placing of Hemo-Car-T on clinical hold was a setback, we are clear on the particular area in which additional information is required, and we are encouraged by the [US Food & Drug Administration]'s response to our plans to resolve the issues. We remain confident and committed to progressing Hemo-Car-T to clinical trials as the company's next step. We have put measures in place to allow us to achieve this milestone, including the new agreement with Prevail InfoWorks and the investment by Prevail Partners, which gives a clear signal of the project's value even at this pre-clinical phase. Meanwhile, the prospects for our other cutting-edge assets continue to be positive, and CBR in particular is beginning to attract real attention."

----------

Lansdowne Oil & Gas PLC - North Celtic Sea-focused oil and gas company - In the six months that ended June 30, pretax loss widens to GBP16.1 million from GBP158,000 a year earlier. This is due to a one-off impairment of intangible assets of GBP15.9 million. Says it remains confident of amicable resolution with Ireland over Barryroe oil field, after receiving a letter in May from the Irish Department of the Environment, Climate & Communications, advising that the minister would not grant the lease undertaking, as sought, on grounds of financial capability. Says: "We continue to maintain that the failure to allow the Barryroe oil and gas field to progress to development is against the best interests of Ireland."

----------

Metals One PLC - London-based mining company, which is focused on battery metals projects in Finland and Norway - In the six months that ended June 30, pretax loss narrows to GBP118,893 from GBP154,371 a year earlier, as administrative expenses narrow to GBP118,893 from GBP184,017. Chair Alastair Clayton says: "The six-month period...was incredibly busy for the company as it worked towards completion of its [initial public offering] and concurrent acquisitions of European brownfield battery metals projects which occurred after the reporting period. With European brownfield projects, experienced partners, and funded work programmes in place, our projects are well positioned for rapid advancement as we seek to establish ethically mined sources of critical minerals, including nickel, in Europe, close to future customers. Exploration in Norway is well underway with Kingsrose, whilst in Finland we are finalising plans to commence phase one drilling in the near future. We look forward to updating shareholders on further news as we continue our work programmes."

----------

NetScientific PLC - London-based investment firm focused on life science, sustainability and technology companies - In the six months that ended June 30, pretax loss narrows to GBP1.6 million from GBP1.7 million a year earlier. Total income during the period was up to GBP1.2 million from GBP656,000 a year earlier, with revenue up to GBP770,000 from GBP391,000. Chief Executive Officer Ilian Iliev says: "During the first half of 2023 we have made significant progress and achieved important milestones as we continue to successfully execute on our 'evergreen' strategy, covering core operating costs through a combination of corporate finance fees and value creation services fees via our wholly owned subsidiary, EMV Capital. We have also demonstrated our ability to generate profitable partial exits from our portfolio, even in the absence of a strong [mergers & acquisitions] or [initial public offering] market. This essential funding for our portfolio companies has helped to facilitate the execution of their growth strategies and preparations for forthcoming scale-up investment rounds as well as supporting the appreciating fair value of NetScientific's direct holdings. In such a challenging venture capital landscape, characterised by macroeconomic volatility and industry fluctuations, our in-house fundraising capacity distinguishes us from many of our peers."

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
15 Apr 2024 11:06

NetScientific investee secures funding to develop product range

(Alliance News) - NetScientific PLC on Monday said its portfolio company ProAxsis Ltd secured GBP1.8 million in investment.

Read more
27 Mar 2024 18:47

TRADING UPDATES: Empire Metals targets key milestones in Australia

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
13 Mar 2024 17:04

NetScientific "significantly" advances strategic goals

(Alliance News) - NetScientific PLC on Wednesday released a portfolio and strategy update.

Read more
23 Jan 2024 18:39

TRADING UPDATES: Esken's Southend Airport faces further allegations

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
1 Dec 2023 11:59

IN BRIEF: NetScientific investee DeepTech Recycling bags GBP1 million

NetScientific PLC - technology and life sciences investor - Portfolio company DeepTech Recycling Ltd closes GBP1 million fundraising. DeepTech, in which NetScientific holds a 30% stake, is a company focused on chemical recycling of plastic waste. Last December, it bought the assets of Recycling Technologies Ltd out of administration. The fundraise is carried out via an advance share subscription agreement and is the first closing of a target investment programme of around GBP3 million, with further investment anticipated within the next six months.

Read more
9 Nov 2023 19:41

IN BRIEF: NetScientific's portfolio company updates on cancer trial

NetScientific PLC - London-based deep tech and life sciences-focused venture capital investor -

Read more
6 Nov 2023 12:00

IN BRIEF: NetScientific says Ventive on fire with new investment

NetScientific PLC - London-based deep tech and life sciences-focused venture capital investor - Says portfolio company Ventive, a London-based designer and manufacturer of heating and ventillation solutions, has successfuly closed a new investment of around GBP900,000. Funding included GBP316,000 from existing shareholders and the conversion of two existing convertible loans valued at about GBP600,000. Investment is part of Ventive's proposed GBP1 million to GBP1.5 million programme, with further investments expected by April 30. NetScientific now holds an 11% total equity stake in Ventive, with a post-investment fair value of GBP893,000 - up from GBP52,000 at December 31.

Read more
23 Oct 2023 21:10

NetScientific investee claims promising results in biomarker study

(Alliance News) - NetScientific PLC on Monday said its investee PDS Biotechnology Corp was "encouraged" by study data for its PDS0101 combined with Merck & Co Inc's drug Keytruda.

Read more
3 Oct 2023 17:12

IN BRIEF: NetScientific portfolio company updates on cancer trial

NetScientific PLC - London-based deep tech and life sciences-focused venture capital investment company - Reports that its portfolio company, PDS Biotechnology Corp, has announced updated interim data from the Versatile-002 phase two clinical trial evaluating PDS0101 in combination with Merck & Co Inc's Keytruda in patients with unresectable, recurrent, or metastatic HPV16-positive head and neck squamous cell carcinoma.

Read more
13 Sep 2023 21:32

NetScientific's Q-Bot completes GBP3.5 million investment programme

(Alliance News) - NetScientific PLC on Wednesday said that its portfolio company, Q-Bot, has successfully closed a GBP3.5 million investment programme.

Read more
14 Aug 2023 19:49

IN BRIEF: NetScientific's PDS suffers wider loss as R&D costs mount

NetScientific PLC - London-based investment firm focused on life science, sustainability and technology companies - Portfolio company PDS Biotechnology Corp reports results for the quarter to June 30. Net loss was USD11.5 million, widened from USD5.8 million the year before. Higher loss primarily due to costs incurred in connection with research and development programmes, which more than doubled to USD8.0 million from USD3.8 million. Loss per share of USD0.37 compared to USD0.20 before. Further, PDS reports the successful submission of final clinical protocol and supporting information to the US Food & Drug Administration to initiate phase 3 Versatile-003 trial in the fourth quarter. Adds biomarker data from Versatile-002 will be presented at the European Society for Medical Oncology Congress.

Read more
30 Jun 2023 14:07

TRADING UPDATES: Pendragon quarterly trading momentum maintained

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Jun 2023 14:11

TRADING UPDATES: tinyBuild bemoans disappointing interim performance

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
22 Jun 2023 17:15

IN BRIEF: NetScientific investee Vortex nabs six-figure investment

NetScientific PLC - London-based investment firm focused on life science, sustainability and technology companies - Announces completion of new GBP3.2 million investment round in portfolio company Vortex Biotech Holdings Ltd, led by EMV Capital. NetScientific converted its GBP400,000 loan into equity alongside new Vortex investors. NetScientific now has a 24.98% total equity holding in Vortex. This equates to a post-investment fair value of GBP2.8 million, quadruple the GBP700,000 value reported at December 31.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.